Chimeric antigen receptor (CAR) T cell therapy has markedly improved the survival of patients with relapsed or refractory B cell leukemia/lymphoma and those with multiple myeloma (MM). In addition, cord blood (CB)-derived natural killer (NK) cells transduced with a CD19 CAR were recently reported to be effective for B cell malignancies. However, acute myeloid leukemia (AML)-specific target antigens are difficult to identify. 

The research group of Naoki Hosen (Graduate School of Medicine, The University of Osaka/WPI-IFReC) demonstrated that HLA-DRB1 can serve as a leukemia-specific target of chimeric antigen receptor (CAR) T cells in patients with AML after allogeneic hematopoietic stem cell transplantation (allo-HCT).
(Nature Cancer on March 25, 2025)

Contact

Naoki Hosen

hnaokibldon.med.osaka-u.ac.jp

Cellular Immunotherapy